表紙
市場調查報告書

全球人造器官市場:成長,趨勢,預測

Artificial Organ Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 390780
出版日期 內容資訊 英文 119 Pages
商品交期: 2-3個工作天內
價格
全球人造器官市場:成長,趨勢,預測 Artificial Organ Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 119 Pages
簡介

本報告提供全球人造器官市場相關調查,彙整市場概要和各市場區隔趨勢,各地區趨勢,參與企業的簡介等資料。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長的推動要素·阻礙因素的簡介
  • 推動市場要素
  • 阻礙市場要素
  • 產業的魅力 - 波特的五力分析

第5章 市場區隔

  • 各內臟器官類型
    • 人工心臟
    • 人工腎臟
    • 人工胰臟
    • 人工肺
    • 人工電子耳
    • 其他內臟器官類型
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭環境

  • 企業簡介
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Boston Scientific Corporation
    • Getinge AB
    • Medtronic PLC
    • Abiomed
    • 旭化成醫學
    • Berlin Heart GmbH
    • Carmat SA
    • Edward Lifesciences Corporation
    • Jarvik Heart Inc.
    • Terumo Corporation

第7章 市場機會·未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55177

Market Overview

The global artificial organ market was valued at USD 29,366.67 million in 2018, and is estimated to be valued at USD 44,899.44 million in 2024, witnessing a CAGR of 7.33%. Factors that are driving the market include the rising geriatric population, scarcity of donor organs, and technological advancements in the artificial organ sector.

Advances in medicine and technology and increased awareness about organ donation and transplantation have contributed to a record number of transplants. But the gap between supply and demand continues. According to the US Government Information on Organ Donation and Transplantation, more than 114,000 patients are on the national transplant waiting list, as of December 2018, and on an average, every 10 minutes, another person is added to the waiting list. 34,770 transplants were performed in 2017, and as of November 2018, a total of 33,431 transplants have been performed in 2018. 95% of US adults support organ donation, but only 54% are actually signed up as donors; only three in 1,000 people die in a way that allows for organ donation. The situation is even direr in countries, such as Japan and South Korea, where the organ donation rates are very low. Hence, the scarcity of donor organs is propelling the demand for artificial organs.

Scope of the Report

An artificial organ is a medical device that is implanted or integrated into the body to replicate or augment the natural function of the organ. As per the scope of the report, artificial organs include implantable devices, such as fully artificial hearts and pacemakers, along with organ support machines, such as dialysis and extracorporeal membrane oxygenation (ECMO) machines.

Key Market Trends

Artificial Kidney is Expected to hold its Highest Market Share in the Organ Type

In the organ type segment of the market, an artificial kidney is believed to have the largest market size and is expected to witness a CAGR of 6.21% during the forecast period.

More than 650,000 patients, per year, in the United States and an estimated 2 million patients worldwide are affected by end-stage renal disease (ESRD). Those who live with ESRD make only 1% of the Medicare-covered population, but account for 7% of the Medicare budget. The number of patients in the United States diagnosed with ESRD is increasing by 5% each year. Mortality rates vary depending on the ESRD treatment. After one year of treatment, those on dialysis have a 20-25% mortality rate, with a five-year survival rate of 35%. People who receive transplants have a 3% mortality rate after five years.

As the rate of mortality because of dialysis is increasing, there is increased demand for artificial kidneys, which is propelling the growth of this segment.

North America Dominates the Market and is Expected to Continue its Dominance in the Forecast Period

North America currently dominates the market for artificial organs, and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to increased demand for artificial organs. The United States spends a significant parentage of its GDP each year on healthcare. According to the recent report of the Organization for Economic Co-operation and Development (OECD), 2018, about 18% of the GDP is spent on healthcare. Out of this, a substantial part goes into transplants being performed in the United States. Therefore, the United States holds the largest share in the artificial organ market in the North American region.

Competitive Landscape

The artificial organ market is moderatley competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with less prices. Companies, like B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corporation, Getinge AB, and Medtronic PLC, hold the substantial share in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Introduction to Market Drivers and Restraints
  • 4.3 Market Drivers
    • 4.3.1 Rising Geriatric Population
    • 4.3.2 Scarcity of Donor Organs
    • 4.3.3 Technological Advancements in the Artificial Organ Sector
  • 4.4 Market Restraints
    • 4.4.1 Expensive Procedures
    • 4.4.2 Risks Associated With Artificial Organs
  • 4.5 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers/Consumers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitute Products
    • 4.5.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Organ Type
    • 5.1.1 Artificial Heart
      • 5.1.1.1 Prosthetic Heart Valves
      • 5.1.1.2 Ventricular Assist Devices
      • 5.1.1.3 Cardiac Pacemakers
    • 5.1.2 Artificial Kidney
    • 5.1.3 Artificial Pancreas
    • 5.1.4 Artificial Lungs
    • 5.1.5 Cochlear Implants
    • 5.1.6 Other Organ Types
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 B. Braun Melsungen AG
    • 6.1.2 Baxter International Inc.
    • 6.1.3 Boston Scientific Corporation
    • 6.1.4 Getinge AB
    • 6.1.5 Medtronic PLC
    • 6.1.6 Abiomed
    • 6.1.7 Asahi Kasei Medical Co. Ltd
    • 6.1.8 Berlin Heart GmbH
    • 6.1.9 Carmat SA
    • 6.1.10 Edward Lifesciences Corporation
    • 6.1.11 Jarvik Heart Inc.
    • 6.1.12 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS